Posts

SARS-CoV-2 seasonal behavior traced back to genetics an...

URBANA, Ill. — As the northern hemisphere heads into summer, we may be in for a ...

Brain-belly connection: gut health may influence likeli...

Could changing your diet play a role in slowing or even preventing the developme...

International Nurses Day: World’s oldest children’s nur...

At a recent event to celebrate the Association’s 85th Anniversary, the Associati...

Cervical cancer screening doubles when under-screened w...

CHAPEL HILL, NC — Researchers at the UNC Gillings School of Global Public Health...

AI study finds that patients with Parkinson’s disease s...

Using artificial intelligence (AI) to process natural language, a research group...

FDA Gives Green Light to Eyenovia’s Pupil-Dilating Spray

Eyenovia Inc. – an ophthalmic technology firm setting up the Optejet equipment f...

FDA cites quality issues at Rentschler and Eli Lilly fa...

The FDA has raised concerns publicly following inspections of Eli Lilly and Rent...

Virogenetics Inc. Announces Pilot Clinical Trial of Dia...

Enzolytics, Inc., made an announcement recently that its wholly-owned subsidiary...

FDA Doubtful Over Benefit of Sarepta’s Duchenne Gene Th...

It is unclear if the first gene therapy for Duchenne muscular dystrophy will be ...

Synlogic’s SYNB1934 receives orphan drug status from US...

SYNB1934 has also received orphan drug designation from the European Medicines A...

China clears sNDA for combination therapy of NSCLC

Approval was given to TYVYT (sintilimab injection) plus bevacizumab and chemothe...

Amgen enlists TScan’s target discovery platform for Cro...

TScan will receive $30m upfront and a possible $500m in milestones to aid T cell...

Gilead wins patent battle with US government over HIV P...

A federal jury has ruled in favour of Gilead, stating that the government’s pate...

First-in-class migraine treatment Vydura approved for N...

The Scottish Medicines Consortium includes the first gepant for migraines on NHS...

Sobi agrees to buy CTI BioPharma for $1.7bn

The acquisition will strengthen Sobi's haematology medicines portfolio with the ...

Alvotech and Polifarma sign agreement to commercialise ...

The trial will assess the efficacy, safety and immunogenicity of the therapy com...